Biotechnology company TILT Biotherapeutics has presented encouraging results for its TILT-123 therapy at the European Society for Medical Oncology (ESMO) Congress 2026. The company reported on the Phase Ib portion of its PROTA study, which is evaluating TILT-123 (igrelimogene litadenorepvec) in combination with MSD’s anti-PD-1 therapy Keytruda… Read More
The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, have announced an exclusive worldwide license and collaboration agreement with Georgiamune for GIM-621. GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumours. It is one… Read More
The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly). The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer. Patients with locally advanced… Read More
BioNTech has announced the first topline results from the AHEAD-MERIT Phase II/III clinical trial for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or tenu-ra). The clinical trial is evaluating BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent… Read More
AC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD). ACI-7104 is designed to induce… Read More
A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma. The trial, called TOPICAL, is led by The Christie NHS Foundation Trust and will take… Read More
A little‑known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester’s Cancer Research UK Manchester Institute, have found. Their discovery, published in Immunity, centres on activated dendritic cells, a specialised population of immune cells that orchestrate the body’s… Read More
Dispatch Bio has dosed the first participant in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, oesophageal adenocarcinoma, and gastroesophageal adenocarcinoma. The participant was treated with both DV-10 and ide-cel… Read More
Alistair Henry, Executive Vice President Chief Scientific Officer at UCB, explains that various factors that are helping drive the development of T-cell engagers (TCEs). … Read More
The latest issue of Drug Discovery World is out now. The DDW Summer 2026 issue examines the multi-compound approach to autism, the outlook for GLP-1 therapies and highlights drug discovery innovators and Investors – investment challenges and opportunities for drug developers. It also included features on: The importance of tech and collaboration for immunotherapies The… Read More
Dr Rosanne Dunn, Co-Founder and Chief Scientific Officer at HaemaLogiX, explores how discovery of a new class of tumour‑specific antigens is transforming how we treat plasma cell dyscrasias. For more than two decades, progress in multiple myeloma has been marked by sustained advances in drug development… Read More
This eBook, sponsored by Sartorius, explores the latest developments in cancer research and why it matters, advances in immunotherapy, unlocking new frontiers in cancer research and ways that experts are driving the industry. Download this exclusive eBook to learn more about: Autotaxin… Read More
This eBook, sponsored by Sartorius, explores the latest developments in cancer research and why it matters, advances in immunotherapy, unlocking new frontiers in cancer research and ways that experts are driving the industry.
Professor Mimi Tang discusses multi-year follow up from the PPOIT-003 Phase IIb programme and how these data help clarify distinct post-treatment clinical states, including remission and desensitisation, and their implications for durability, adherence, and real-world patient experience once structured therapy is complete. Recent multi-year data from the PPOIT-003 and PPOIT-003LT… Read More
Biotechnology company Commit Biologics has appointed Thomas Montgomery Andresen as CEO as it aims to take its complement-powered immune engagers into clinic. Commit described Andresen as “a serial biotech entrepreneur”, with over 20 years of experience building high-value biotech ventures at the intersection of therapeutic innovation and bioengineering. … Read More
Andrea Pfeifer, Co-Founder and CEO of AC Immune, examines how active immunotherapies could lead to a better treatment of Alzheimer’s disease. Alzheimer’s… Read More
